Elizabeth Yeu Lin - Nov 4, 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Medical Officer
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Nov 4, 2024
Transactions value $
$0
Form type
4
Date filed
11/6/2024, 04:40 PM
Previous filing
Jun 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +41.1K $0.00 41.1K Nov 4, 2024 Common Stock 41.1K $46.21 Direct F1
transaction TARS Restricted Stock Units Award $0 +27.3K $0.00 27.3K Nov 4, 2024 Common Stock 27.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.